#Canada #Duchesnay #Blainville #pharmaceutical #Investissement

Duchesnay Pharmaceutical Group's Global Expansion

Duchesnay Pharmaceutical Group (DPG), a leading name in women's health and recognized as the winner of the 2024 ADRIQ Life Sciences Innovation Award, is set to enhance its global presence with the installation of a state-of-the-art pharmaceutical tablet printer at its facility in Blainville, Quebec. This advancement, enabled by the support from Investissement Québec's grand V initiative and the Government of Quebec's ESSOR program, marks a significant milestone in DPG's commitment to responding to the growing international demand for its products.

The new tablet printer boasts an impressive production capacity of up to 150,000 tablets per hour, which will play a pivotal role in increasing DPG's output while ensuring the quality of its renowned flagship product, aimed at supporting women's health, which is currently exported to over 40 countries. The expansion is strategically aligned with DPG’s ambitions to penetrate ten new international markets within the next two years, reflecting its dedication to meeting the increasing global demand for its offerings.

Mélanie Therrien, DPG's Vice President of Finance and Corporate Affairs, shared insights about the company’s vision, stating, "As we further our global growth, our commitment to excellence and innovation in supporting women's health remains unwavering. The new machine allows us not only to meet the increasing demand but also to optimize our manufacturing processes sustainably. Thanks to the grand V initiative, we are progressing in our global expansion strategy."

Bicha Ngo, President and CEO of Investissement Québec, further emphasized the significance of this acquisition, stating, "Supported by the grand V initiative, Duchesnay Pharmaceutical Group has made strides toward enhanced productivity with its new cutting-edge printer. This equipment will allow for substantial increases in production capacity and foster growth within the pharmaceutical sector, validating our ongoing support for innovative companies."

About Duchesnay Pharmaceutical Group

Duchesnay Pharmaceutical Group is comprised of six interconnected pharmaceutical entities that specialize in various aspects of healthcare, particularly focused on women's health, rare diseases, and generic medications. Its main offices and production facility are located in Blainville, Quebec, where it operates at a high standard of innovation and quality.

Among DPG's entities are Duchesnay Canada and Duchesnay USA, both dedicated solely to women's health, and Medunik Canada and Medunik USA, focusing on treatments for rare diseases. Its specialized companies, Analog Pharma Canada and Analog Pharma, are known for their range of orphan generics. Through its cutting-edge manufacturing capabilities, DPG distributes innovative treatments to over 50 countries worldwide.

The company is one of eight selected participants in Canada’s Global Hypergrowth Project, designed to provide personalized support for accelerated growth. DPG's achievements have not only been recognized with the 2024 Life Sciences Innovation Award but also with the prestigious 2024 Bernard-Landry Award for impactful leadership in Quebec's research and innovation sector, bestowed upon its president Éric Gervais.

DPG is at the forefront of pharmaceutical innovation, emphasizing proprietary research alongside collaborations to deliver treatments for a wide range of medical conditions, including oncology and urology, as well as several rare diseases. The company prides itself on its healthy workplace culture, flexibility in its work environment, and robust commitment to environmental responsibility. Additionally, DPG actively participates in community engagement through support for various charitable organizations, showcasing its commitment to corporate social responsibility.

For those interested in learning more about Duchesnay Pharmaceutical Group, visit their official website at duchesnaypharmaceuticalgroup.com and follow them on LinkedIn for the latest updates.

Duchesnay's forward-thinking approach and commitment to improving women's health through innovation exemplify its role as a key player in the global pharmaceutical landscape, paving the way for future growth and community well-being.

Source: Duchesnay Pharmaceutical Group (DPG)